Jump to content

Psoralen

From Wikipedia, the free encyclopedia
Psoralen
Chemical structure of psoralen
Names
Preferred IUPAC name
7H-Furo[3,2-g][1]benzopyran-7-one
Identifiers
3D model (JSmol)
152784
ChEBI
ChEMBL
ChemSpider
ECHA InfoCard 100.000.581 Edit this at Wikidata
EC Number
  • 200-639-7
KEGG
UNII
  • InChI=1S/C11H6O3/c12-11-2-1-7-5-8-3-4-13-9(8)6-10(7)14-11/h1-6H checkY
    Key: ZCCUUQDIBDJBTK-UHFFFAOYSA-N checkY
  • O=C1/C=C\c2cc3ccoc3cc2O1
Properties
C11H6O3
Molar mass 186.16 g/mol
Melting point 158 to 161 °C (316 to 322 °F; 431 to 434 K)
Hazards
GHS labelling:
GHS07: Exclamation mark
Warning
H302, H315, H319, H335
P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, P501
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
checkY verify (what is checkY☒N ?)

Psoralen (also called psoralene) is the parent compound in a family of naturally occurring organic compounds known as the linear furanocoumarins. It is structurally related to coumarin by the addition of a fused furan ring, and may be considered as a derivative of umbelliferone. Psoralen occurs naturally in the seeds of Psoralea corylifolia, as well as in the common fig, celery, parsley, West Indian satinwood, and in all citrus fruits. It is widely used in PUVA (psoralen + UVA) treatment for psoriasis, eczema, vitiligo, and cutaneous T-cell lymphoma; these applications are typically through the use of medications such as Methoxsalen. Many furanocoumarins are extremely toxic to fish, and some are deposited in streams in Indonesia to catch fish.[1]

Uses

[edit]

Psoralen is a mutagen, and is used for this purpose in molecular biology research. Psoralen intercalates into DNA and on exposure to ultraviolet (UVA) radiation can form monoadducts and covalent interstrand cross-links (ICL) with thymines, preferentially at 5'-TpA sites in the genome, inducing apoptosis. Psoralen plus UVA (PUVA) therapy can be used to treat hyperproliferative skin disorders like psoriasis and certain kinds of skin cancer.[2] Unfortunately, PUVA treatment itself leads to a higher risk of skin cancer.[3]

An important use of psoralen is in PUVA treatment for skin problems such as psoriasis and, to a lesser extent, eczema and vitiligo. This takes advantage of the high UV absorbance of psoralen. The psoralen is applied first to sensitise the skin, then UVA light is applied to address the condition. Psoralens are also used in photopheresis, where they are mixed with the extracted leukocytes before UV radiation is applied.

Despite the photocarcinogenic properties of psoralen,[4][5] it was used as a tanning activator in sunscreens until 1996.[6] Psoralens are used in tanning accelerators, because psoralen increases the skin's sensitivity to light. Some patients have had severe skin loss after sunbathing with psoralen-containing tanning activators.[7] Patients with lighter skin colour suffer four times as much from the melanoma-generating properties of psoralens than those with darker skin.[6] Psoralens short term side effects include nausea, vomiting, erythrema, pruritus, xerosis, skin pain due to phototoxic damage of dermal nerve and may cause cutaneous and genital skin malignancies.[8]

An additional use for optimized psoralens is for the inactivation of pathogens in blood products. The synthetic amino-psoralen, amotosalen HCl, has been developed for the inactivation of infectious pathogens (bacteria, viruses, protozoa) in platelet and plasma blood components prepared for transfusion support of patients. Prior to clinical use, amotosalen-treated platelets have been tested and found to be non-carcinogenic when using the established p53 knockout mouse model.[9] The technology is currently in routine use in certain European blood centers and has been recently approved in the US.[10][11][12][13]

Chemistry

[edit]

Psoralen intercalates into the DNA double helix where it is ideally positioned to form one or more adducts with adjacent pyrimidine bases, preferentially thymine, upon excitation by an ultraviolet photon.

Several physicochemical methods have been employed to derive binding constants for psoralen-DNA interactions. Classically, two chambers of psoralen and buffered DNA solution are partitioned by a semi-permeable membrane; the affinity of the psoralen for DNA is directly related to the concentration of the psoralen in the DNA chamber after equilibrium. Water solubility is important for two reasons: pharmacokinetics relating to drug solubility in blood and necessitating the use of organic solvents (e.g. DMSO). Psoralens can also be activated by irradiation with long wavelength UV light. While UVA range light is the clinical standard, research that UVB is more efficient at forming photoadducts suggests that its use may lead to higher efficacy and lower treatment times.[14]

The photochemically reactive sites in psoralens are the alkene-like carbon-carbon double bonds in the furan ring (the five-member ring) and the pyrone ring (the six-member ring). When appropriately intercalated adjacent to a pyrimidine base, a four-center photocycloaddition reaction can lead to the formation of either of two cyclobutyl-type monoadducts. Ordinarily, furan-side monoadducts form in a higher proportion. The furan monoadduct can absorb a second UVA photon leading to a second four-center photocycloaddition at the pyrone end of the molecule and hence the formation of a diadduct or cross-link. Pyrone monoadducts do not absorb in the UVA range and hence cannot form cross-links with further UVA irradiation.[15]

Another important feature of this class of compounds is their ability to generate singlet oxygen, although this process is in direct competition with adduct formation and may be an alternate pathway for the dissipation of excited state energy.

Research on psoralen has historically focused on interactions with DNA and RNA (in particular, ICL formation). Psoralen, however, has also been shown to block signaling of the ErbB2 receptor which is overexpressed in certain aggressive types of breast cancer.[16] A synthetic derivative of bergapten, 5-(4-phenoxybutoxy)psoralen, shows promise as an immunosuppressant by inhibiting a specific potassium channel. Its structure prevents intercalation into DNA, and it only very weakly produces singlet oxygen, majorly reducing unwanted toxicity and mutagenicity in vivo. This has implications for the treatment of various autoimmune diseases (e.g. multiple sclerosis, type-1 diabetes, and rheumatoid arthritis).[17] While cell-surface modification and ion channel blocking are two newly discovered mechanisms of action, much research remains to be done.

Structure

[edit]

Most furanocoumarins can be regarded as derivatives of either psoralen or angelicin. Psoralen and its derivatives are often referred to as the linear furanocoumarins, so called since they exhibit a linear chemical structure. Important linear furanocoumarins include xanthotoxin (also called methoxsalen), bergapten, imperatorin, and nodakenetin.

Structures of angelicin, xanthotoxin, bergapten and nodekenetin
Structures of angelicin, xanthotoxin, bergapten and nodekenetin

The structure of psoralen was originally deduced by identifying the products of its degradation reactions. It exhibits the normal reactions of the lactone of coumarin, such as ring opening by alkali to give a coumarinic acid or coumaric acid derivative. Potassium permanganate causes oxidation of the furan ring, while other methods of oxidation produce furan-2,3-carboxylic acid.

Synthesis

[edit]

Psoralen is difficult to synthesize because umbelliferone undergoes substitution at the 8-position rather than at the desired 6 position. Benzofuran reacts preferentially in the furan ring rather than in the benzene ring. However, the 7-hydroxy derivative of 2,3-dihydrobenzofuran (also called coumaran) does undergo substitution at the desired 6-position allowing the following synthesis of the coumarin system via a Gattermann–Koch reaction followed by a Perkin condensation using acetic anhydride. The synthesis is then completed by dehydrogenation of the five-membered ring to produce the furan ring.

Synthesis of psoralen from 6-hydroxycoumaran
Synthesis of psoralen from 6-hydroxycoumaran

Biosynthesis

[edit]

Psoralen originates from coumarins in the shikimate pathway; its biosynthesis is shown in the figure below. The aromatic ring in 6 is activated at positions ortho to the hydroxyl group, and is alkylated by 5, an alkylating agent. The dimethylallyl group in 7 then undergoes cyclization with the phenol group to give 8. This transformation is catalysed by a cytochrome P-450-dependent monooxygenase17 (psoralen 5-monooxygenase), and cofactors (NADPH) and molecular oxygen.[18]

A biosynthetic pathway in which psoralen is formed is shown in the figure below. A second P-450-dependent monooxygenase enzyme (psoralen synthase) then cleaves off 10 (in the form of 11) from 8 to give 1. This pathway does not involve any hydroxylated intermediate, and cleavage is postulated to be initiated by a radical reaction.[18]

Synthesis of psoralen from 6-hydroxycoumaran
Synthesis of psoralen from 6-hydroxycoumaran

Plant sources

[edit]

Ficus carica (fig) is probably the most abundant source of psoralens. They are also found in small quantities in Ammi visnaga (bisnaga), Pastinaca sativa (parsnip), Petroselinum crispum (parsley), Levisticum officinale (lovage), Foeniculum vulgare (fruit, i.e., fennel seeds), Daucus carota (carrot), Psoralea corylifolia (babchi), Apium graveolens (celery), bergamot oil (bergapten, bergamottin).[19]

Repair of psoralen DNA adducts

[edit]

PUVA treatment produces both DNA interstrand crosslinks (ICLs) and monoadducts. The ICLs introduced by psoralen are highly genotoxic to actively replicating cells. The covalent linkage impedes replication fork progression. Thus unlinking the ICL is required before replication can resume. The initial steps in repair ordinarily involve incisions in one parental strand on both sides of the crosslink.[20] Subsequently, repair of the lesion can occur by an accurate or an inaccurate process.

The accurate process for repairing crosslinks is homologous recombinational repair (HRR). This involves replacing the damaged information using the intact information from another homologous chromosome in the same cell. Escherichia coli cells deficient in HRR are highly sensitive to PUVA compared to wild-type cells.[21] HRR appears to be efficient. In E. coli, even though one or two unrepaired crosslinks are sufficient to inactivate a cell, a wild-type cell can repair and therefore recover from 53 to 71 psoralen crosslinks.[21] In the yeast Saccharomyces cerevisiae HRR is a major pathway for accurately removing psoralen-crosslinks.[22] In wild-type yeast, the recombination events associated with crosslink removal by HRR are predominantly non-crossover gene conversion events. Psoralen crosslinks in virus DNA also appear to be removed by a recombinational repair process as occurs in SV40 virus infected cells,[23] and in herpes simplex virus infected cells.[24]

One inaccurate process for repairing psoralen crosslinks appears to employ a DNA polymerase to fill in the gap formed in the strand with the two incisions. This process is inaccurate because the complementary un-incised strand still retains a portion of the crosslink and thus cannot serve as an adequate template for accurate repair synthesis. Inaccurate repair synthesis can cause mutation. Psoralen monoadducts in the template DNA strand may also cause inaccurate replication bypass (translesion synthesis) that can lead to mutation. In phage T4, the increase in mutation observed after PUVA treatment was found to reflect translesion synthesis by wild-type DNA polymerase, likely due to imperfect proof reading capability.

Analysis of nucleic acids structures

[edit]

Psoralens can reversibly crosslink nucleic acids double helices, and therefore have been used extensively for the analysis of interactions and structures for both DNA and RNA.[25][26]

References

[edit]
  1. ^ Dean, F. M. (1963). Naturally occurring oxygen ring compounds. London: Butterworths.
  2. ^ Wu Q, Christensen LA, Legerski RJ, Vasquez KM (June 2005). "Mismatch repair participates in error-free processing of DNA interstrand crosslinks in human cells". EMBO Rep. 6 (6): 551–7. doi:10.1038/sj.embor.7400418. PMC 1369090. PMID 15891767.
  3. ^ Momtaz K, Fitzpatrick TB (April 1998). "The benefits and risks of long-term PUVA photochemotherapy". Dermatol Clin. 16 (2): 227–34. doi:10.1016/S0733-8635(05)70005-X. PMID 9589196.
  4. ^ M. J. Ashwood-Smith; G. A. Poulton; M. Barker; M. Mildenberger E (1980). "5-Methoxypsoralen, an ingredient in several suntan preparations, has lethal, mutagenic and clastogenic properties". Nature. 285 (5): 407–9. Bibcode:1980Natur.285..407A. doi:10.1038/285407a0. PMID 6991953. S2CID 4345680.
  5. ^ Zajdela F, Bisagni E (1981). "5-Methoxypsoralen, the melanogenic additive in suntan preparations, is tumorigenic in mice exposed to 365 nm UV radiation". Carcinogenesis. 2 (2): 121–7. doi:10.1093/carcin/2.2.121. PMID 7273295.
  6. ^ a b Autier P.; Dore J.-F.; Cesarini J.-P. (1997). "Should subjects who used psoralen suntan activators be screened for melanoma?". Annals of Oncology. 8 (5): 435–7. doi:10.1023/A:1008205513771. PMID 9233521.
  7. ^ Nettelblad H, Vahlqvist C, Krysander L, Sjöberg F (December 1996). "Psoralens used for cosmetic sun tanning: an unusual cause of extensive burn injury". Burns. 22 (8): 633–5. doi:10.1016/S0305-4179(96)00028-9. PMID 8982544.
  8. ^ Shenoi, Shrutakirthi D.; Prabhu, Smitha; Indian Association of Dermatologists, Venereologists and Leprologists (November 2014). "Photochemotherapy (PUVA) in psoriasis and vitiligo". Indian Journal of Dermatology, Venereology and Leprology. 80 (6): 497–504. doi:10.4103/0378-6323.144143. ISSN 0973-3922. PMID 25382505.
  9. ^ Ciaravino V, McCullough T, Dayan AD: Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated)platelets. Human Exp Toxicol 2001;20:533–550
  10. ^ Osselaer; et al. (2009). "Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use". Transfusion. 49 (7): 1412–1422. doi:10.1111/j.1537-2995.2009.02151.x. PMID 19389022. S2CID 25477437.
  11. ^ Cazenave; et al. (2010). "An active hemovigilance program characterizing the safety profile of 7,483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment". Transfusion. 50 (6): 1210–1219. doi:10.1111/j.1537-2995.2009.02579.x. PMID 20113450. S2CID 32119458.
  12. ^ "FDA approves first pathogen reduction system to treat plasma". www.fda.gov. Archived from the original on 2014-12-25.
  13. ^ "FDA approves pathogen reduction system to treat platelets". www.fda.gov. Archived from the original on 2014-12-25.
  14. ^ Alexandru D. Buhimschi; Francis P. Gasparro (September 2013). "UVA and UVB-Induced 8-Methoxypsoralen Photoadducts and a Novel Method for their Detection by Surface-Enhanced Laser Desorption Ionization Time-of-Flight Mass Spectrometry (SELDI-TOF MS)". Journal of Photochemistry and Photobiology. 90 (1): 241–246. doi:10.1111/php.12171. PMID 24102188. S2CID 206270126.
  15. ^ Gasparro, Francis P., ed. (1988). Psoralen DNA photobiology. 1. Boca Raton, Fl: CRC Pr. ISBN 978-0-8493-4379-7.
  16. ^ Wenle Xia; David Gooden; Leihua Liu; Sumin Zhao; Erik J. Soderblom; Eric J. Toone; Wayne F. Beyer Jr; Harold Walder; Neil L. Spector (February 14, 2014). Cheng, Jin (ed.). "Photo-Activated Psoralen Binds the ErbB2 Catalytic Kinase Domain, Blocking ErbB2 Signaling and Triggering Tumor Cell Apoptosis". PLOS ONE. 9 (2): e88983. Bibcode:2014PLoSO...988983X. doi:10.1371/journal.pone.0088983. PMC 3925176. PMID 24551203.
  17. ^ Alexander Schmitz; Ananthakrishnan Sankaranarayanan; Philippe Azam; Kristina Schmidt-Lassen; Daniel Homerick; Wolfram Hänsel; Heike Wulff (November 2005). "Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases". Molecular Pharmacology. 68 (5): 1254–1270. doi:10.1124/mol.105.015669. PMID 16099841. S2CID 6931552.
  18. ^ a b Dewick, P.M. (2009). Medicinal Natural Products: A Biosynthetic Approach (3rd ed.). Wiley. pp. 164–5. ISBN 978-0-471-49641-0.
  19. ^ "Dr. Duke's Phytochemical and Ethnobotanical Databases". U.S. Department of Agriculture, Agricultural Research Service. Retrieved October 6, 2018.
  20. ^ Cole RS, Levitan D, Sinden RR (1976). "Removal of psoralen interstrand cross-links from DNA of Escherichia coli: mechanism and genetic control". J. Mol. Biol. 103 (1): 39–59. doi:10.1016/0022-2836(76)90051-6. PMID 785009.
  21. ^ a b Sinden RR, Cole RS (1978). "Repair of cross-linked DNA and survival of Escherichia coli treated with psoralen and light: effects of mutations influencing genetic recombination and DNA metabolism". J. Bacteriol. 136 (2): 538–47. doi:10.1128/JB.136.2.538-547.1978. PMC 218577. PMID 361714.
  22. ^ Saffran WA, Ahmed A, Binyaminov O, Gonzalez C, Gupta A, Fajardo MA, Kishun D, Nandram A, Reyes K, Scalercio K, Senior CW (2014). "Induction of direct repeat recombination by psoralen-DNA adducts in Saccharomyces cerevisiae: defects in DNA repair increase gene copy number variation". DNA Repair (Amst.). 21: 87–96. doi:10.1016/j.dnarep.2014.05.011. PMID 24969513.
  23. ^ Hall JD (1982). "Repair of psoralen-induced crosslinks in cells multiply infected with SV40". Mol. Gen. Genet. 188 (1): 135–8. doi:10.1007/bf00333007. PMID 6294477. S2CID 5843939.
  24. ^ Hall JD, Scherer K (1981). "Repair of psoralen-treated DNA by genetic recombination in human cells infected with herpes simplex virus". Cancer Res. 41 (12 Pt 1): 5033–8. PMID 6272987.
  25. ^ Cimino GD, Gamper HB, Isaacs ST, Hearst JE (1985). "Psoralens as Photoactive Probes of Nucleic Acid Structure and Function: Organic Chemistry, Photochemistry, and Biochemistry". Annual Review of Biochemistry. 54: 1151–1193. doi:10.1146/annurev.bi.54.070185.005443. PMID 2411210.
  26. ^ Lu Z, Zhang QC, Lee B, Flynn RA, Smith MA, Robinson JT, Davidovich C, Gooding AR, Goodrich KJ, Mattick JS, Messirov JP, Cech TR, Chang HY (2016). "RNA Duplex Map in Living Cells Reveals Higher-Order Transcriptome Structure". Cell. 165 (5): 1267–1279. doi:10.1016/j.cell.2016.04.028. PMC 5029792. PMID 27180905.

Further reading

[edit]
  1. Dean, F.M. (1963). Naturally Occurring Oxygen Ring Compounds. London: Butterworths.
  2. The Merck Index (7th ed.). Rahway NJ: Merck. 1960.
[edit]
Wikimedia Commons has media related to Psoralen.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Psoralen&oldid=1229562447"